Exemption number (b)(4).The device was not returned for evaluation.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.The reported patient effects of dyspnea, prolapse and stenosis are listed in the xience sierra, everolimus eluting coronary stent system (eecss), electronic instructions for use as known patient effects of coronary stenting procedures.A conclusive cause for the reported patient effects, and the relationship to the product, if any, cannot be determined.There is no indication of a product quality issue with respect to manufacture, design or labeling of the device.
|
Patient id: (b)(6).It was reported that on (b)(6) 2019, a 2.5 x 28 mm xience sierra stent was implanted in the 1st obtuse marginal artery.After stent implantation, optical coherence tomography noted insignificant plaque shift and additional post dilatation was performed.Post procedure, the plaque shift resolved.On (b)(6) 2019, the patient had complaints of shortness of breath and weakness.Percutaneous coronary intervention was performed and in-stent restenosis was noted.Angioplasty was performed, using a high pressure sculpting balloon.The event resolved the same day.No additional information was provided.
|